Wolfe Research raises Texas Instruments stock price target on growth

Texas Instruments delivered a Q1 revenue beat of $4.83B versus $4.52B expected and EPS of $1.68 versus $1.36 consensus, with gross margin at 58% and data center revenue up 90% year over year. Wolfe Research raised its price target to $315 from $260 and lifted 2026/2027 estimates, citing stronger industrial and datacenter trends and over $10B of 2027 free cash flow potential. Additional upside came from follow-on analyst target increases, though the stock already trades near its 52-week high and at a premium valuation.

Analysis

The market is starting to treat TXN less like a cyclical analog and more like a quasi-infrastructure cash compounder, but that re-rating is now vulnerable to diminishing returns. The key second-order issue is that a higher capex path would not just depress near-term FCF; it also signals management sees a multi-year demand runway in datacenter/industrial that the sell-side may be extrapolating too linearly. If the incremental growth is driven by a narrow subset of customers, the upside becomes much more sensitive to digestion risk than the headline beat suggests.

The most important competitive implication is not for other analogs broadly, but for industrial-capex beneficiaries and adjacent power/MCU suppliers that rely on the same end-market spend. If TXN keeps taking share in datacenter-related power management, then the winners are likely downstream systems integrators and hyperscaler build-out names, while smaller analog peers with less scale may face price pressure as TXN uses its balance sheet to entrench sockets. The SLAB deal is also a subtle signal that TXN wants to broaden its design-in surface area; that can improve resilience, but it usually comes with integration execution risk and a longer payback period than the market models.

Consensus appears to be underpricing duration risk: the stock is being valued as though current demand momentum persists with minimal cyclicality, even though industrial normalization can reverse quickly if purchasing teams reoptimize inventory. The setup is therefore asymmetric over months, not days — near-term momentum can continue, but the multiple leaves little room for any guide-down, margin compression, or a slower-than-expected capex payoff. A modest miss on datacenter sequencing would likely matter more than a small beat because the market is already capitalizing growth at a premium to historical analog multiples.

Contrarianly, the real question is whether the capex hike is a warning disguised as confidence: management may be forced to spend to defend position in an increasingly contested end market. If so, free cash flow estimates could be too high not because revenue disappoints, but because maintenance-plus-growth capex rises faster than expected. That makes the stock less attractive as a pure quality long at current levels and more interesting as a relative-value short against names with cleaner FCF conversion and less reinvestment intensity.

Key Decisions for Investors

• Trim TXN long exposure into strength over the next 1-2 weeks; the stock is close to perfection and the risk/reward is skewed if capex keeps rising faster than FCF.
• For accounts needing analog exposure, rotate from TXN into a basket of higher-mean-reversion names with lower expectations; use TXN as the funding source rather than adding net beta.
• Express a relative-value pair: short TXN / long a cash-generative industrial beneficiary with less reinvestment burden over 3-6 months; the thesis is valuation compression if TXN capex expands again.
• Buy TXN puts or put spreads 3-6 months out only on a pullback, using them as protection against any datacenter digestion or guide-down risk; avoid chasing upside calls at these levels.
• If staying long, scale in only after the next earnings cycle confirms that higher capex is translating into sustained FCF, not just revenue growth; otherwise the multiple is fragile.